Viking Therapeutics
VKTX
107 hedge funds and large institutions have $72.4M invested in Viking Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 38 reducing their positions, and 23 closing their positions.
116% more call options, than puts
Call options by funds: $871K | Put options by funds: $404K
0.44% more ownership
Funds ownership: 34.26% → 34.71% (+0.44%)
5% less capital invested
Capital invested by funds: $76.5M → $72.4M (-$4.06M)
6% less funds holding
Funds holding: 114 → 107 (-7)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
42% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 38
Top Buyers
| 1 |
Millennium Management
New York
|
+$5.86M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$4.38M |
| 3 |
Walleye Capital
New York
|
+$2.63M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.6M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.07M |
Top Sellers
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$7.13M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.89M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.22M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.21M |
| 5 |
Morgan Stanley
New York
|
-$858K |
VKTX Hedge Fund Activity: Q3 2022 in Review
107 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2022, worth a combined $72.4M — down 5.3% from $76.5M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VKTX and 17 opened new positions — a net loss of 6 holders — while 38 trimmed existing stakes and 22 added.
The largest buyer was Millennium Management, adding an estimated $5.86M. The largest seller was Park West Asset Management, exiting entirely with an estimated $7.13M sold.
- 107 institutional investors held Viking Therapeutics (VKTX) as of Q3 2022, down from 114 in Q2 2022.
- Funds reported $72.4M of Viking Therapeutics stock for Q3 2022, down 5.3% quarter-over-quarter.
- 17 funds opened new Viking Therapeutics positions in Q3 2022 and 23 closed out, a net change of -6 holders.
- The largest Viking Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $5.86M added.
- The largest Viking Therapeutics seller in Q3 2022 was Park West Asset Management, an estimated $7.13M sold.
Based on aggregated 13F filings for Q3 2022.